Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab and CHOP in Aggressive Peripheral T-Cell Lymphomas
NCT00363090Phase 2Unknown
- Sponsor
- Odette Cancer Centre
- Start
- Sep 2006
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in peripheral T-cell lymphoma (PTCL), sponsored by Odette Cancer Centre. Status: unknown.
02
Drugs
alemtuzumab
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT00363090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00363090.